Achieve Names Two New Exemplary Healthcare Leaders to its Board of Directors
New Leadership and Financing, up to $354 Million ($180 Million Upfront and $174 Million Dependent on the Exercise of Milestone Warrants), Strengthen Achieve’s Position to Execute Development and Launch of Cytisinicline, if Approved, as the First New Treatment for Nicotine Dependence in Two Decades
SEATTLE and VANCOUVER, British Columbia, April 16, 2026 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV) today announced it has appointed Andrew D. Goldberg, MD, as Chief Executive Officer and as a member of the Board of Directors, effective following the closing of Achieve’s recently announced financing. Dr. Goldberg is a dual board-certified physician who has spent his career at the intersection of medicine and business, advising, investing in, and governing pharmaceutical companies as they navigate the complexities of commercialization.
“On behalf of the Board, I’m pleased to welcome Andrew as CEO,” said Thomas King, chairman of Achieve’s Board of Directors. “His clinical experience as a practicing physician, combined with his proven track record in healthcare investment and commercial strategy, make him ideally suited to drive operational excellence, financial execution and shareholder value for Achieve. I also want to thank Rick for his exceptional leadership in building this Company. His continued presence on the Board will be invaluable as we work to bring cytisinicline to market.”
Richard Stewart, outgoing President & CEO and co-founder of Achieve, said, “I am proud of the company we have built and the progress we have made advancing cytisinicline toward potential FDA approval. Achieve is well-positioned to help millions of Americans overcome nicotine dependence. I have full confidence in Andrew’s ability to execute our commercial strategy and bring cytisinicline to market. I look forward to supporting the Company as a member of the Board as we work towards delivering this much-needed treatment to the people who need it most.”
“As a physician in both intensive care units and emergency departments, I have witnessed firsthand the devastating harms smoking inflicts on the lives of patients and their families,” said Dr. Goldberg, incoming CEO. “Cytisinicline represents a generational public health opportunity to combat both smoking—the leading cause of preventable death—and the rapid rise of vaping, which is putting a new generation at risk. I am honored to build on the excellent work Rick and the Achieve team have done to advance cytisinicline, and I am grateful to our new and existing investors for supporting our mission to deliver a new option to the many millions ready to quit.”